28
Participants
Start Date
November 30, 2009
Primary Completion Date
December 31, 2011
Study Completion Date
March 31, 2012
Lenalidomide (CC-5013)
CC-5013 given PO daily on D1-D14 every 21 days and Paclitaxel administered IV over 1 hour on d1 and 8 every 21 days until tumor progression or unacceptable toxicity
Istituto Oncologico della Svizzera Italiana, Bellinzona
Fondazione IRCSS Istituto Nazionale dei Tumori, Milan
Collaborators (1)
Celgene Corporation
INDUSTRY
Southern Europe New Drug Organization
OTHER